Intercept Pharmaceuticals Inc (NASDAQ:ICPT) CEO Mark Pruzanski purchased 7,812 shares of Intercept Pharmaceuticals stock in a transaction dated Monday, April 9th. The shares were purchased at an average price of $64.00 per share, for a total transaction of $499,968.00. Following the completion of the acquisition, the chief executive officer now owns 11,642 shares of the company’s stock, valued at approximately $745,088. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Intercept Pharmaceuticals stock opened at $70.11 on Thursday. The company has a current ratio of 4.31, a quick ratio of 4.31 and a debt-to-equity ratio of 21.71. The company has a market capitalization of $1,742.96, a P/E ratio of -4.88 and a beta of -1.82. Intercept Pharmaceuticals Inc has a one year low of $51.05 and a one year high of $135.59.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($3.39) by ($1.04). The company had revenue of $37.69 million during the quarter, compared to analyst estimates of $39.01 million. Intercept Pharmaceuticals had a negative return on equity of 267.95% and a negative net margin of 275.18%. Intercept Pharmaceuticals’s revenue was up 173.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($4.84) earnings per share. equities analysts predict that Intercept Pharmaceuticals Inc will post -12.6 earnings per share for the current fiscal year.
Several research firms have recently weighed in on ICPT. Wedbush restated a “buy” rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, December 22nd. Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, March 28th. BidaskClub upgraded Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, January 25th. ValuEngine upgraded Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, April 4th. Finally, Oppenheimer restated a “hold” rating on shares of Intercept Pharmaceuticals in a report on Tuesday, March 20th. Four investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company. Intercept Pharmaceuticals presently has an average rating of “Hold” and an average target price of $128.75.
COPYRIGHT VIOLATION WARNING: “Intercept Pharmaceuticals Inc (ICPT) CEO Acquires $499,968.00 in Stock” was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://dakotafinancialnews.com/2018/04/12/intercept-pharmaceuticals-inc-icpt-ceo-acquires-499968-00-in-stock.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.